Objective: To describe the efficacy and tolerability of continuous nitroglycerin for treatment of hot flashes. Methods: Perimenopausal and postmenopausal women reporting at least seven hot flashes per day were recruited into a single-arm, dose-escalation trial of continuous transdermal nitroglycerin. Participants were started on a generic 0.1 mg/hour nitroglycerin patch applied daily without patch-free periods. During 4 weeks, participants escalated dosage weekly to 0.2, 0.4, or 0.6 mg/hour as tolerated, then discontinued nitroglycerin during the final week. Changes in hot flash frequency and severity were assessed using symptom diaries. Paired t tests examined change in outcomes between baseline and maximal-dose therapy and after discontinuation of nitroglycerin.
M ore than two thirds of U.S. women experience hot flashes (a.k.a. vasomotor symptoms) during menopause, and up to a one fourth of women suffer from symptoms severe enough to require treatment. 1, 2 Although estrogen therapy is effective in suppressing hot flashes, it is associated with increased long-term risk of cardiovascular and thromboembolic events when combined with progestogen to prevent endometrial hyperplasia. 3, 4 In addition, estrogen therapy is contraindicated in women with estrogen-sensitive cancers and those with hot flashes in the setting of selective estrogen receptor modulator or aromatase inhibitor therapy. As a result, there is widespread interest in identifying nonhormonal treatments for hot flashes that are not only effective, but well tolerated and easy to use.
Although most other attempts to identify nonhormonal treatments for hot flashes have focused on potential central nervous system triggering mechanisms, the final physiologic pathway underlying the hot flash is peripheral vasodilation. Clinical studies have shown that nitric oxide (NO) plays an important role in mediating peripheral vasodilation during hot flashes, with local cutaneous blockade of NO synthase suppressing hot flash-related vasodilation. [5] [6] [7] One pharmacologic agent with direct and potent effects on NO-mediated vasodilation is nitroglycerin, an organic nitrate that is widely used to treat chest pain in patients with coronary disease. Intermittent use of nitroglycerin triggers release of NO, promotes vascular smooth muscle relaxation, and triggers vasodilation.
However, continuous use of nitroglycerin rapidly leads to tolerance to the drug's vasodilatory effects and cross-tolerance to endogenous nitrates, as a result of enhanced NO degradation. [8] [9] [10] [11] [12] [13] Although this tolerance limits the usefulness of nitroglycerin for chest pain, it offers a potentially innovative approach to treating hot flashes, because women who develop cross-tolerance should experience a marked reduction in hot flashes as a result suppression of NO-mediated peripheral vasodilation.
To explore the potential efficacy and tolerability of continuous nitroglycerin for hot flashes, we conducted a single-arm, dose-escalation trial in perimenopausal and postmenopausal women.
METHODS
Participants were recruited from the San Francisco Bay area in 2013 and 2014 using a combination of communitybased media efforts (newspaper advertisements, community fliers), targeted mailings to female patients at the University of California San Francisco (UCSF) Medical Center with diagnostic codes suggestive of hot flashes, and recruitment from a database of past research participants interested in women's health studies. Eligible women had to be between 40 and 60 years of age and report an average of at least seven hot flashes per 24 hours on a validated 7-day screening symptom diary. [14] [15] [16] Women also had to report nine or fewer menstrual periods in the past year or a history of bilateral oophorectomy, or to have measured serum follicle stimulating hormone levels greater than 30 mU/mL. Women were excluded if they reported using other clinical treatments for hot flashes in the past 3 months (eg, hormone therapy, selective serotonin or norepinephrine reuptake inhibitors, clonidine, gabapentin) or if they were already using nitrate-based medications. To avoid enrolling women who might need to use nitroglycerin for chest pain or who might be at increased risk of chest pain with withdrawal of nitrate therapy, study staff excluded women reporting a history of coronary disease, hypertrophic cardiomyopathy, diabetes mellitus, or two or more risk factors for coronary disease (ie, smoking, hypertension, or hyperlipidemia with clinician-directed pharmacologic treatment). Also excluded were women with a history of chronic headache, known sensitivity to adhesives, or blood pressure less than 100/60 mm Hg. All participants provided informed consent according to the protocol approved by the institutional review board of UCSF.
Generic nitroglycerin patches from Mylan Pharmaceuticals Inc (Canonsburg, PA) in the four existing commercially available doses (0.1, 0.2, 0.4, and 0.6 mg/h) were purchased by the UCSF Compounding and Research Support Pharmacy and distributed to participants on a weekly basis. All eligible participants were initially instructed to apply a 0.1 mg/hour patch on a daily basis to any clean, dry, hairless area of skin on the body except the extremities below the knee or elbow for 1 week. Participants applied a new patch just before bedtime, immediately after removing the older patch, and were instructed to avoid any patch-free episodes that might interfere with development of tolerance. Those who were successful in applying and changing the 0.1 mg/hour patch for 1 week but continued to report persistent bothersome hot flashes subsequently underwent dose escalation on a weekly basis to 0.2, 0.4, or 0.6 mg/hour as tolerated. Women who reported being completely satisfied with the improvement in their hot flashes or had concerns about side effects on a higher-dose patch were permitted to remain at a lower dose. Dose escalation was therefore designed to be participantdirected and to reflect both symptom control and medication tolerability, as would be expected in clinical practice. During the final study week, women were instructed to wean off nitroglycerin during a 1-to 3-day period, by switching to a lower patch dose on each successive day until they were no longer taking nitroglycerin, to allow assessment for posttreatment rebound in hot flashes. Adherence was tracked by medication diaries, in which participants directly affixed their used patches to the diary after removing them and indicated the date and time that patches were changed.
Hot flash frequency and severity were measured using a validated symptom diary shown to have good test-retest reliability and sensitive to change in past trials of hot flash interventions. [14] [15] [16] [17] During each week of the study, women were instructed to record each hot flash they experienced and rate its severity as: (1) mild (sensation of heat without sweating), (2) moderate (sensation of heat with sweating, not preventing activity), or (3) severe (severe sensation of heat and sweating, resulting in cessation of activity); severity definitions were provided with the diary. To facilitate realtime recording of symptoms, the diary was designed to be small and portable, and women were instructed to carry the diary with them during the day and keep it at their bedside at night. Participants also received $25 in gift cards for each completed diary returned during the study.
The primary clinical outcome of the study was change in the average daily frequency of any hot flashes (averaged during each 7-day diary period). Diary data were also used to assess change in daily frequency of moderate-to-severe hot flashes as a secondary outcome. A cumulative 7-day hot flash severity score was also calculated for each week of the study by summing the severity rating for each hot flash reported during each 7-day diary period. 15, 16 Paired t tests were used to examine average change in outcomes between baseline and maximal-dose therapy, and between maximal-dose therapy and after discontinuation of nitroglycerin treatment. Normal distribution of change values was confirmed using Shapiro-Wilk tests. Changes between baseline and each dose of nitroglycerin (0.1, 0.2, 0.4, and 0.6 mg/h) were evaluated for women who used any of these doses for at least a 7day period; dose effects were tested both categorically and linearly using linear models with repeated measures. All analyses were carried out in SAS Version 9.4 (SAS Institute, Cary, NC).
Safety was assessed by systematically querying participants about any negative changes in health at all follow-up visits after initiation of therapy; all negative changes reported TRANSDERMAL NITROGLYCERIN FOR HOT FLASHES were recorded as adverse events on standardized forms. Participants were also given telephone numbers to call study coordinators in between scheduled visits to report additional adverse events. Resting blood pressure and heart rate were also measured at baseline and each follow-up visit, with intent to discontinue therapy in participants with blood pressure less than 90/60 mm Hg or in those with blood pressure less than 100/60 mm Hg and symptoms suggestive of hypotension. Women were informed in advance about headache, lightheadedness, and/or low blood pressure as potential side effects of nitroglycerin, and also were given a one-page pamphlet on strategies for managing these symptoms.
RESULTS
Of the 119 women who inquired about the study, 64 were found ineligible, and 36 failed to complete screening procedures or ultimately opted not to enroll. The most common reasons for ineligibility were insufficient frequency of hot flashes (N ¼ 22), use of exclusionary medications (N ¼ 16), and exclusionary medical conditions (N ¼ 7). Of the 19 enrolled participants, mean (AESD) age was 51.4 (AE4.3) years, and 8 (42%) were racial/ethnic minorities (including 4 Asian, 3 Black, and 1 Latina). Three (16%) had undergone bilateral oophorectomy. Six (32%) were using aromatase inhibitors, and four (21%) were using selective estrogen receptor modulators. Mean body mass index (BMI) was 25.2 (AE4.5) kg/m 2 , with three women (16%) being overweight (BMI !25 kg/m 2 ) and three (16%) being obese (BMI !30 kg/m 2 ). On average, women reported 10.6 (AE2.1) hot flashes and 7.2 (AE3.7) moderate-to-severe hot flashes per day, and the mean 7day hot flash severity score was 20.0 (AE7.7). Mean systolic and diastolic blood pressure were 129.9 (AE16.9) and 79.1 (AE12.5) mm Hg, respectively.
Of the 19 women who started on nitroglycerin, 2 (10%) developed headache on the initial 0.1 mg/hour dose, leading them to discontinue treatment before the first outcomes assessment. Of the remaining 17 women, 11 (65%) opted to escalate to 0.6 mg/hour, 3 (18%) escalated to 0.4 mg/hour, 2 (12%) escalated to 0.2 mg/hour, and 1 (6%) chose to remain on 0.1 mg/hour.
Among the 17 women completing the 6-week study, the average daily frequency of any hot flashes decreased from 10.7 (AE3.1) at baseline to 5.0 (AE2.5) at highest dose (54% average decrease, P for paired t test <0.01; Fig. 1 ). The average daily frequency of moderate-to-severe hot flashes decreased from 7.7 (AE3.8) at baseline to 2.3 (AE2.6) at highest dose (69% average decrease, P for paired t test <0.01). Average 7-day hot flash severity scores also decreased from 20.4 (AE7.7) to 8.5 (AE6.0) at highest dose (58% decrease, P for paired t test <0.01).
Among the 17 women providing outcomes data, higher doses of nitroglycerin therapy were associated with greater reduction in frequency of hot flashes (Table 1) . Average reduction in daily frequency of any hot flashes from baseline was 28% for 0.1 mg/hour, 34% for 0.2 mg/hour, 39% for 0.4 mg/hour, and 53% for 0.6 mg/hour dose (P < 0.01 for linear trend with increasing dose). Average reduction in daily frequency of moderate-to-severe hot flashes was 35% for 0.1 mg/hour, 39% for 0.2 mg/hour, 54% for 0.4 mg/hour, and 65% for 0.6 mg/hour dose (P < 0.01 for linear trend).
After women discontinued nitroglycerin, the average daily frequency of any hot flashes was 6.0 (AE3.5) (23% average increase compared to maximal-dose therapy, P ¼ 0.041; Fig. 1 ). The average daily frequency of moderate-to-severe hot flashes was 4.4 (AE3.5) per day (96% average increase from maximal-dose therapy, P < 0.001). Hot flash frequency and severity were assessed by symptoms diaries in which women recorded each hot flash they experienced and rated its severity as mild, moderate, or severe. The average daily frequency of (1) any hot flashes, and (2) moderate-to-severe hot flashes, was determined over a 7-day period at baseline (pretreatment), during successive 7-day periods on each dose of nitroglycerin, and during a 7-day period during weaning and discontinuation of nitroglycerin. Among the 17 participants providing outcomes data, maximum dose of nitroglycerin was 0.6 mg/hour for 11 women, 0.4 mg/hour for 3 women, 0.2 mg/hour for 2 women, and 0.1 mg/hour for one woman.
HUANG ET AL
Eleven participants reported adverse events during the study, including five with headache, three with lightheadedness, three with nausea, two with rash, and one with palpitations (categories not mutually exclusive). Among the 17 women who tolerated the initial dose of nitroglycerin, none discontinued treatment because of adverse events, regardless of highest dose achieved. No serious adverse events (defined as death, disability, or hospitalization) were reported during the study. Average blood pressure was 127/79 (AE14/9.2) mm Hg, 129 /78 (AE17/9.7) mm Hg, 130/81 (AE16/10) mm Hg, and 125/77 (AE13/11) mm Hg on 0.1 mg, 0.2, 0.4, and 0.6 mg/hour nitroglycerin, respectively, and no women had medication withheld for low blood pressure.
DISCUSSION
These results suggest that continuous nitroglycerin has the potential to substantially reduce the frequency of hot flashes, particularly moderate-to-severe flashes, in perimenopausal and postmenopausal women. During a 4-week period, women reported an average 54% decrease in frequency of any hot flashes, 69% reduction in frequency of moderate-to-severe hot flashes, and 58% decrease in cumulative hot flash severity scores between baseline and maximum tolerated therapy (ranging from 0.1 to 0.6 mg/h). Although this trial did not include a placebo group, the magnitude of improvement in hot flashes among women taking continuous nitroglycerin exceeded that reported in multiple prior trials of nonhormonal pharmacologic therapies. [18] [19] [20] [21] [22] Furthermore, participants reported an average 22% increase in frequency of any hot flashes and 81% increase in frequency of moderate-to-severe hot flashes after discontinuation of nitroglycerin, demonstrating that improvements observed on nitroglycerin did not result solely from reversion to the mean.
Our findings also suggest that improvement in hot flashes associated with nitroglycerin may be dose dependent, with significantly greater reductions in the frequency and severity of symptoms with increasing dose. Nevertheless, some women reported substantial improvements in their symptoms at low doses (eg, 0.2 mg/h or less) and opted not to further escalate therapy. In addition, dose escalation was performed sequentially over time, and the effects of higher dose nitroglycerin therapy may have been partially influenced by longer duration of treatment.
Results also suggest that continuous transdermal nitroglycerin therapy may be tolerated well by many, but not all perimenopausal or postmenopausal women with hot flashes.
Headache is a known potential side effect of nitroglycerin that limits its use for treatment of ischemic chest pain, and primary nitroglycerin-induced headache thought to be caused by medication-induced vasodilation of intracranial blood vessels. 23 Although the risk of headache should be lower among women who use the medication continuously and thus develop tolerance to its vasodilatory effects, five participants in this trial reported headache at some point in the study, and two developed headache that led them to discontinue treatment within a few days of starting the lowest dose. Nevertheless, findings suggest that women who are able to tolerate 0.1 mg/hour nitroglycerin are likely to be able to continue therapy for at least a month, and in most cases to escalate to higher-dose therapy on 0.2, 0.4, or 0.6 mg/hour.
Limitations of this study include its modest size, single-arm design, and relatively short duration of follow-up. Exclusion of women with a known history of or multiple risk factors for coronary disease also precluded assessment of safety in that population. Future larger, randomized, and blinded trials are indicated to test the efficacy and safety of continuous nitroglycerin over longer periods of treatment in a broader array of postmenopausal women.
CONCLUSIONS
Given the potential long-term adverse effects of hormone therapy, many women are interested in nonhormonal treatments for hot flashes. The present study provides preliminary evidence that continuous nitroglycerin therapy may offer a novel and potentially effective treatment for hot flashes, presumably by targeting peripheral vasodilation mechanisms. 
